## Table 2 |
|||

Base-case costs estimates ($, year 2012 values) and utilities |
|||

Parameter |
Median |
Range |
Description and references |

Cost of EGFR genotyping per patient | 507.9 | 381–634.9 | Local charge |

Cost of gefitinib per 250 mg ($) | 77.8 | 38.9–77.8^{*} |
Local charge |

Cost of follow-up per unit ($) | 55.6 | 41.7–69.4 | [34] |

Cost of 2nd-line chemotherapy per cycle ($) | 2352.7 | 1921.1–4383.3 | Calculation |

Cost of palliative care in end-of-life treatment ($) | 3664.3 | 21.4–48750.2 | Calculation |

Cost of supportive care per cycle ($) | 337.5 | 158.7–793.7 | Calculation |

Cost of SAEs in platinum-based chemotherapy per cycle ($) | 507.4 | 189.7–825.0 | Calculation |

Expenditures of SAEs in maintenance treatment per cycle | |||

Cost of SAEs in Gefitinib strategy per cycle ($) | Formula^{#} |
Calculation | |

Utilities | |||

Utility of PFS | 0.65 | 0.26–0.87 | [29] |

Utility of OS | 0.47 | 0.19–0.58 | [29] |

* The range was assumed for a one-way sensitivity analysis.

# Formula: Cost of SAEs in platinum-based chemotherapy per cycle × Cumulative probability of SAEs in maintenance strategy / Cumulative probability of SAEs in platinum-based chemotherapy.

Zhu * et al.*

Zhu * et al.* *BMC Cancer* 2013 **13**:39 doi:10.1186/1471-2407-13-39